General Updates
- Unpaid Dividend 31.03.2022
- Approval of in-house R&D facilities u/s 35(2AB) of Income Tax Act, 1961.
- Intimation under regulation 30(2) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.
- Press Release on FDA Approval for manufacturing Hydroxychloroquine Sulphate Bulk Drug (API) and formulation of its tablets.
- Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.